fbpx Skip to main content

TUESDAY, Oct. 13, 2020 — There are considerable racial- and ethnicity-based cancer health disparities in the United States, according to a report published online Sept. 16 by the American Association for Cancer Research.

John D. Carpten, Ph.D., from the University of Southern California in Los Angeles, and colleagues discussed cancer health disparities in the U.S. population, highlighting areas of progress in reducing cancer health disparities.

The authors note that the burden of cancer is not shouldered equally by all segments of the U.S. population, with African Americans having the highest overall cancer death rate of any racial or ethnic group. Disparities are seen in cancer screening rates, with the lowest colorectal cancer screening rates seen among Hispanics and the lowest breast cancer screening rates in American Indians/Alaska Natives. Cancer patients from certain racial and ethnic minorities and underserved populations are often less likely to receive the recommended standard of care; for some cancers, racial and ethnic disparities in outcomes could be eliminated if all patients had equal access to care. Furthermore, racial and ethnic minorities are underrepresented in clinical trials. Cancer health disparities could be overcome by enhancing diversity in training and in the cancer workforce and through science-based public policy.

“This inaugural and historic progress report will provide the world with a comprehensive baseline understanding of our progress toward recognizing and eliminating cancer health disparities from the standpoint of biological factors, clinical management, population science, public policy, and workforce diversity,” Carpten said in a statement.

Full Text

You May Also Like::  Addressing COVID-19's Disparate Impact on Black Americans

“Keeping up with the indications and adverse reactions to immune checkpoint inhibitors can be a full-time job. Cutaneous side effects occur in up to 45% of patients treated with ipilimumab and 34% of patients treated with nivolumab and pembrolizumab.” https://bit.ly/3FGtxtd

.@spfnomt: This month’s #DermWorld article “Estate planning 101” is especially important for young physicians to read. The long, all-consuming years between adolescence and physicianhood can become a blur...https://bit.ly/3FxOtCv

That’s a wrap #AAD2023! 5 days of soaking up knowledge from dermatologists on topics such as hidradenitis, melasma, & dietary triggers of common dermatoses.

I LOVED the #womenshealth focused sessions on vulvar dermatoses and pregnancy medication safety.


New approach uses microbiome to treat skin disease by repairing the injured microbiome that allowed inflammation to flare up in the first place, rather than reducing the inflammation after the fact. https://bit.ly/3Jt6H9v

Load More